Ipsen Acquires Memo Therapeutics AG to Advance First-in-Class BK Polyomavirus Antibody

Ipsen has announced the acquisition of Memo Therapeutics AG, primarily for its clinical-stage antibody, potravitug, aimed at treating BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. Phase II clinical trial results for potravitug demonstrated significant viral load reduction and histological improvement in BKPyV-associated nephropathy, a serious complication that can lead to graft loss.